Jazz Acquires Actio Biosciences for $820M, Adding Rare Epilepsy Drug ABS-1230
JAZZ has more than doubled off its 52-week low of $106.65.
Summary
Jazz Pharmaceuticals is acquiring privately-held Actio Biosciences for $820 million upfront, with up to $500 million in milestones. The deal brings ABS-1230, a first-in-class KCNT1 inhibitor for a rare, severe epilepsy with no approved therapies. Early clinical data showed meaningful seizure reductions, and the FDA has accepted the drug into its new RDEP program to accelerate development. This follows Jazz's recent Zepzelca setback and builds on its Epidiolex franchise, directly strengthening its rare epilepsy pipeline. The transaction also includes a spin-out of a new private company focused on other rare neurological diseases, with Jazz taking a minority stake. The upfront payment is material but manageable given Jazz's $16.7 billion market cap and strong Q2 cash flows.
At the time of this announcement, JAZZ was trading at $255.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.7B. The 52-week trading range was $106.65 to $265.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.